Search results
Results from the WOW.Com Content Network
Acetazolamide is a first generation carbonic anhydrase inhibitor and it decreases the ocular fluid and osmolality in the eye to decrease intraocular pressure. [5] [6] Common side effects include numbness, ringing in the ears, loss of appetite, vomiting, and sleepiness. [2]
Acetazolamide is an inhibitor of carbonic anhydrase. It is used for glaucoma, epilepsy (rarely), idiopathic intracranial hypertension, and altitude sickness. For the reduction of intraocular pressure (IOP), acetazolamide inactivates carbonic anhydrase and interferes with the sodium pump, which decreases aqueous humor formation and thus lowers IOP.
An undesirable side-effect of acetazolamide is a reduction in aerobic endurance performance. Other minor side effects include a tingle-sensation in hands and feet. Although a sulfonamide, acetazolamide is a non-antibiotic and has not been shown to cause life-threatening allergic cross-reactivity in those with a self-reported sulfonamide allergy.
Rebound intracranial hypotension is very common in people with SIH after an EBP, and can be treated with acetazolamide, topiramate, or in severe cases therapeutic lumbar puncture; most cases are not severe. Rare side effects include subdural or spinal bleeding, infection, and seizure, [9] though EBPs do not carry a significant infectious risk ...
Less-common side effects can include excess air or gas in your stomach, burping, heartburn, indigestion, fast heartbeat, low blood sugar, low energy and fatigue, or even gallstones, Dr. Comite says.
Additional medications that are being considered for prevention but require further research to determine efficacy and treatment guidelines include acetazolamide, salmeterol, tadalafil (and other PDE5 inhibitors), and dexamethasone. [15] [3] [17] Acetazolamide has proven to be clinically effective, but formal studies are lacking. Salmeterol is ...
Once we knew I wasn’t having any negative side effects from Zepbound, my doctor increased my dose to 5 mg for about a month, and then eventually to 7.5 mg.
In drug development, serious adverse event (SAE) is defined as any untoward medical occurrence during a human drug trial that at any dose Results in death; Is life-threatening; Requires inpatient hospitalization or causes prolongation of existing hospitalization; Results in persistent or significant disability/incapacity